Manila Times Business
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
- Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile - -The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the Phase III part of the ESLIM-02 study of sovleplenib in patient
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Kaldvík AS - Updated financial calendar
3h ago
Scott Alldridge Releases New Book Showing Why Most Cybersecurity Breaches Stem from Governance Failures Rather Than Technology Weaknesses
3h ago
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
3h ago
NowVertical Appoints Andre Garber as Interim CEO of the Company
3h ago